Hepion Pharmaceuticals Inc
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC) and other chronic liver diseases in the United States. It develops Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical ex… Read more
Hepion Pharmaceuticals Inc (HEPA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.362x
Based on the latest financial reports, Hepion Pharmaceuticals Inc (HEPA) has a cash flow conversion efficiency ratio of -0.362x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.38 Million) by net assets ($3.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hepion Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Hepion Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Hepion Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hepion Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
B2digital Inc
PINK:BTDG
|
0.021x |
|
Balwin Properties Ltd
JSE:BWN
|
0.029x |
|
Potash America Inc
PINK:PTAM
|
0.003x |
|
Petro Viking Energy Inc
PINK:PTRVF
|
0.001x |
|
LATTICE SEMICONDUCT
MU:LTT
|
0.063x |
|
Metalyst Forgings Limited
NSE:METALFORGE
|
-0.048x |
|
SOLARVEST BIOENER
F:0ZJ
|
N/A |
|
Groupe Bruxelles Lambert SA
MU:EAI
|
N/A |
Annual Cash Flow Conversion Efficiency for Hepion Pharmaceuticals Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Hepion Pharmaceuticals Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-1.86 Million | $-18.22 Million | 9.776x | +274.08% |
| 2023-12-31 | $7.28 Million | $-40.89 Million | -5.616x | -700.86% |
| 2022-12-31 | $49.86 Million | $-34.96 Million | -0.701x | -108.85% |
| 2021-12-31 | $93.00 Million | $-31.22 Million | -0.336x | +15.84% |
| 2020-12-31 | $40.52 Million | $-16.17 Million | -0.399x | +17.65% |
| 2019-12-31 | $15.62 Million | $-7.57 Million | -0.484x | +93.88% |
| 2018-12-31 | $1.98 Million | $-15.65 Million | -7.922x | -257.35% |
| 2017-12-31 | $3.70 Million | $-8.21 Million | -2.217x | +82.36% |
| 2016-12-31 | $1.32 Million | $-16.56 Million | -12.565x | -346.74% |
| 2015-12-31 | $3.44 Million | $-9.67 Million | -2.813x | -705.22% |
| 2014-12-31 | $-2.93 Million | $-1.36 Million | 0.465x | 0.00% |
| 2013-12-31 | $-2.93 Million | $-1.36 Million | 0.465x | +81819.04% |
| 2012-12-31 | $-140.50K | $-79.70 | 0.001x | -- |